Drag a card by its title · ⚙ to size, swap or remove

The company

Heron Therapeutics, Inc.

HRTX · Nasdaq

Health CareBiotechnologyNot moving yet

HRTX stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 39.0% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 52
Industry in uptrend: 18% -14 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $0
Officials’ trades on record: 1
Institutions holding: 151 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

21 Apr – 20 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

Who	Did	Amount	Traded
Ashley Hinson House: U.S. House ClerkIA01	soldspouse	$1k–$15k	31 Mar 2021filed 5 Apr 2021

Insiders

Buy orders, 12 months0

Sale orders, 12 months0

Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders151-4 on the quarter

New · exited20 · 26

Reported value$57.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Rubric Capital Management LPunchanged · filed 14 Aug 2026	30,046,828$12.8M	00.0%
Clearline Capital LPreduced · filed 14 Aug 2026	11,383,961$4.9M	-851,278−7.0%
BlackRock, Inc.added · filed 7 Aug 2026	10,550,750$4.5M	+444,328+4.4%
Velan Capital Investment Management LPunchanged · filed 14 Aug 2026	8,753,290$3.7M	00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026	7,782,741$3.3M	-27,588−0.4%
Tejara Capital Ltdadded · filed 11 Aug 2026	6,510,795$2.8M	+174,040+2.7%
TANG CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 2026	6,250,000$2.7M	00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	4,270,980$1.8M	+260,893+6.5%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026	4,070,101$1.7M	-3,560,426−46.7%
JW Asset Management, LLCunchanged · filed 7 Aug 2026	3,751,073$1.6M	00.0%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Craig A. Collard Chief Executive Officer · last 19 Oct 20261 · 0

Duarte Ira EVP, Chief Financial Officer · last 19 Oct 20261 · 0

William P. Forbes EVP, Chief Development Officer · last 19 Oct 20262 · 0

Mark Earl Hensley Chief Operating Officer · last 6 Aug 20260 · 0

Adam Morgan Director · last 30 Jan 20262 · 0

Craig A. Johnson Director · last 30 Jan 20260 · 4

Michael Kaseta Director · last 30 Jan 20260 · 0

Sharmila Dissanaike Director · last 30 Jan 20260 · 0

Thomas Cusack Director · last 30 Jan 20260 · 0

Waage Christian Director · last 30 Jan 20261 · 4

David Efraim Rosen 10% owner · last 15 Oct 20251 · 0

Susan Rodriguez Director · last 31 Jan 20250 · 0

Same industry

MRNA ModernaLeading+167%

IOVA Iovance BiotherapeuticsLeading+141%

ABCL AbCellera BiologicsLeading+57%

ENTX Entera BioLeading+52%

HALO Halozyme TherapeuticsLeading+48%

XERS Xeris Biopharma HoldingsLeading+47%

XNCR XencorLeading+41%

HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202573.3%

Operating profit marginFY 2025 · to 31 Dec 2025-1.6%

Free cash flow marginFY 2025 · to 31 Dec 2025-18.0%

Return on capital employedFY 2025 · to 31 Dec 2025-1.6%

Research spendFY 2025 · to 31 Dec 20258.0%

Share count trendFY 2025 · to 13 Feb 20260.1%

Cash and equivalentsFY 2025 · to 31 Dec 2025$28.6M

Free cash flowFY 2025 · to 31 Dec 2025−$27.9M

Analyst forecasts

No analyst forecasts yet.